Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing

被引:11
作者
Caselli, Desiree [1 ]
Mariani, Marcello [2 ]
Colomba, Claudia [3 ,4 ]
Ferrecchi, Chiara [5 ]
Cafagno, Claudio [1 ]
Trotta, Daniela [6 ]
Carloni, Ines [7 ]
Dibello, Daniela [8 ]
Castagnola, Elio [2 ]
Arico, Maurizio [6 ]
机构
[1] Azienda Osped Univ Consorziale Policlin Bari, Childrens Hosp Giovanni XXIII, Infect Dis, I-70124 Bari, Italy
[2] IRCCS Ist Giannina Gaslini, Pediat Infect Dis Unit, I-16147 Genoa, Italy
[3] Univ Palermo, Dept Hlth Promot Maternal & Child Care, Internal Med & Med Specialties G Alessandro, I-90133 Palermo, Italy
[4] G Di Cristina Hosp, ARNAS Civ Cristina Benfratelli, Div Pediat Infect Dis, I-90127 Palermo, Italy
[5] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet & Maternal, I-16126 Genoa, Italy
[6] ASL Pescara, S Spirito Hosp, Pediat, I-65124 Pescara, Italy
[7] Salesi Childrens Hosp, Dept Mother & Child Hlth, I-60123 Ancona, Italy
[8] Childrens Hosp Giovanni XXIII, Pediat Orthoped & Traumatol, I-70125 Bari, Italy
来源
CHILDREN-BASEL | 2024年 / 11卷 / 01期
关键词
dalbavancin; soft tissue infection; acute bacterial skin and skin structure infections (ABSSSIs); bone infection; ACUTE BACTERIAL SKIN; RESISTANT STAPHYLOCOCCUS-AUREUS; PEDIATRIC-PATIENTS; EFFICACY; THERAPY; BURDEN; TRENDS;
D O I
10.3390/children11010078
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Acute bacterial skin and skin structure infections (ABSSSI) and osteoarticular infections compound the burden of morbidity, mortality and prolonged hospitalizations among gram-positive infections. Dalbavancin, a second-generation, intravenous lipoglycopeptide, due to its prolonged half-life, can be a valuable alternative in their treatment when administered as inpatient treatment at the price of an extended hospital stay. Between October 2019 and September 2023, 31 children and adolescents were treated with dalbavancin because of bone and joint infections (n = 12 patients, 39%), ABSSSI (n = 13 patients, 42%), mainly for the limbs, facial cellulitis or complicated ABSSSI (n = 6 patients, 19%), at five Italian pediatric centers. Microbiological study provided gram-positive bacterial isolate in 16 cases, in 11 cases from a positive blood culture; 9 of them were MRSA. Twenty-five patients were initially treated with a different antibiotic therapy: beta-lactam-based in 18 patients (58%), glycopeptide-based in 15 patients (48%) and daptomycin in 6 (19%). The median time that elapsed between admission and start of dalbavancin was 18 days. A total of 61 doses of dalbavancin were administered to the 31 patients: 16 received a single dose while the remaining 15 patients received between two (n = 9) and nine doses. The frequency of administration was weekly in five cases or fortnightly in nine patients. Median length of stay in hospital was 16 days. Median time to discharge after the first dose of dalbavancin was 1 day. Treatment was very well-tolerated: of the 61 administered doses, only four doses, administered to four patients, were associated with an adverse event: drug extravasation during intravenous administration occurred in two patients, with no sequelae; however, in two patients the first administration was stopped soon after infusion start: in one (ID #11), due to headache and vomiting; in another (ID #12) due to a systemic reaction. In both patients, drug infusion was not repeated. None of the remaining 29 patients reported treatment failure (resistant or recurrent disease) or an adverse effect during a median follow-up time of two months. The use of dalbavancin was safe, feasible and also effective in shortening the hospital stay in children and adolescents.
引用
收藏
页数:11
相关论文
共 27 条
[1]   Vancomycin Infusion Reaction - Moving beyond "Red Man Syndrome" [J].
Alvarez-Arango, Santiago ;
Ogunwole, S. Michelle ;
Sequist, Thomas D. ;
Burk, Caitlin M. ;
Blumenthal, Kimberly G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14) :1283-1286
[2]   Effectiveness, safety and cost analysis of dalbavancin in clinical practice [J].
Arrieta-Loitegui, Maria ;
Manuel Caro-Teller, Jose ;
Ortiz-Perez, Sara ;
Lopez-Medrano, Francisco ;
San Juan-Garrido, Rafael ;
Miguel Ferrari-Piquero, Jose .
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (01) :55-58
[3]   Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model [J].
Baldoni, Daniela ;
Tafin, Ulrika Furustrand ;
Aeppli, Sandrine ;
Angevaare, Eline ;
Oliva, Alessandra ;
Haschke, Manuel ;
Zimmerli, Werner ;
Trampuz, Andrej .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (03) :220-225
[4]   The role of dalbavancin in skin and soft tissue infections [J].
Bassetti, Matteo ;
Peghin, Maddalena ;
Carnelutti, Alessia ;
Righi, Elda .
CURRENT OPINION IN INFECTIOUS DISEASES, 2018, 31 (02) :141-147
[5]   Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection [J].
Boucher, Helen W. ;
Wilcox, Mark ;
Talbot, George H. ;
Puttagunta, Sailaja ;
Das, Anita F. ;
Dunne, Michael W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (23) :2169-2179
[6]   Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients [J].
Carrothers, Timothy J. ;
Lagraauw, H. Maxime ;
Lindbom, Lars ;
Riccobene, Todd A. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (02) :99-105
[7]   A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections [J].
Dimopoulou, Dimitra ;
Mantadakis, Elpis ;
Koutserimpas, Christos ;
Samonis, George .
ANTIBIOTICS-BASEL, 2023, 12 (10)
[8]   A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection [J].
Dunne, Michael W. ;
Puttagunta, Sailaja ;
Giordano, Philip ;
Krievins, Dainis ;
Zelasky, Michael ;
Baldassarre, James .
CLINICAL INFECTIOUS DISEASES, 2016, 62 (05) :545-551
[9]  
ema, Xydalba|European Medicines Agency
[10]   Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update [J].
Esposito, Silvano ;
Bassetti, Matteo ;
Concia, Ercole ;
De Simone, Giuseppe ;
De Rosa, Francesco G. ;
Grossi, Paolo ;
Novelli, Andrea ;
Menichetti, Francesco ;
Petrosillo, Nicola ;
Tinelli, Marco ;
Tumbarello, Mario ;
Sanguinetti, Maurizio ;
Viale, Pierluigi ;
Venditti, Mario ;
Viscoli, Claudio .
JOURNAL OF CHEMOTHERAPY, 2017, 29 (04) :197-214